C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

被引：13
|
作者：
Jacobson, Caron A. [1 ]
Maus, Marcela, V [2 ]
机构：
[1] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
BLOOD ADVANCES | 2020年 / 4卷 / 22期
关键词：
INHIBITOR IBRUTINIB; MALIGNANCIES; POPULATION; EFFICACY; OUTCOMES; BTK;
D O I：
10.1182/bloodadvances.2020003391
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed the natural history of relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphoma. Based on these results, CD19 CAR T cells have since been tested in largely incurable lymphomas, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma, with promising early results that raise the question of whether this cellular immunotherapy could have curative potential and change the natural history of these diseases. This article reviews these results and this hypothesis.
引用
收藏
页码：5858 / 5862
页数：5
相关论文
共 50 条
  • [31] Cutaneous lymphomas: emerging concepts - Could follicular helper T-cells play a role in primary cutaneous CD4+small/medium-sized pleomorphic T-cell lymphomas?
    Ferenczi, Katalin
    JOURNAL OF CUTANEOUS PATHOLOGY, 2009, 36 (06) : 717 - 718
  • [32] Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study
    Iovino, Lorenzo
    Wu, Qian Vicky
    Voutsinas, Jenna
    Panaite, Lorena
    Mullane, Erin
    Lynch, Ryan C.
    Ujjani, Chaitra
    Smith, Stephen D.
    Gopal, Ajay K.
    Till, Brian G.
    Milano, Filippo
    Chow, Victor
    Gauthier, Jordan
    Turtle, Cameron J.
    Maloney, David G.
    Shadman, Mazyar
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (24) : 5976 - 5983
  • [33] Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive
    Agostinelli, Claudio
    Hartmann, Sylvia
    Klapper, Wolfram
    Korkolopoulou, Penelope
    Righi, Simona
    Marafioti, Teresa
    Piccaluga, Pier Paolo
    Patsouris, Efstratios
    Hansmann, Martin-Leo
    Lennert, Karl
    Pileri, Stefano A.
    HISTOPATHOLOGY, 2011, 59 (04) : 679 - 691
  • [34] Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
    Hill, LaQuisa C.
    Rouce, Rayne H.
    Wu, Mengfen J.
    Wang, Tao
    Ma, Royce
    Zhang, Huimin
    Mehta, Birju
    Lapteva, Natalia
    Mei, Zhuyong
    Smith, Tyler S.
    Yang, Lina
    Srinivasan, Madhuwanti
    Burkhardt, Phillip M.
    Ramos, Carlos A.
    Lulla, Premal
    Arredondo, Martha
    Grilley, Bambi
    Heslop, Helen E.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2024, 143 (13) : 1231 - 1241
  • [35] Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells
    Karnik, Sushant
    Pham, Minh Thu
    Keerthipati, Pooja
    Padalia, Zinkal
    Carson, Julie
    Ho, Tony
    Morawa, Ewelina
    Will, Matthias
    Terrett, Jonathan
    Dequeant, Mary-Lee
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Anti-T Cell Receptor Vß Chain-Specific CAR-iNKT Cells As a Precise Strategy to Treat Mature T Cell Lymphomas
    Rowan, Aileen G.
    Ponnusamy, Kanagaraju
    Ren, Hongwei
    Taylor, Graham Phillip
    Cook, Lucy
    Karadimitris, Anastasios
    BLOOD, 2022, 140 : 10257 - 10258
  • [37] Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
    Svoboda, Jakub
    Ballard, Hatcher J.
    Chong, Elise A.
    LaRose, Meredith I.
    Bair, Steven M.
    Namoglu, Esin C.
    Hughes, Mitchell E.
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Barta, Stefan K.
    Gerson, James N.
    Weber, Elizabeth
    Walling, Chase
    Ruella, Marco
    Frey, Noelle V.
    Porter, David L.
    Schuster, Stephen J.
    BLOOD, 2019, 134
  • [38] Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
    Schaefer, Andrew
    Huang, Ying
    Kittai, Adam
    Maakaron, Joseph E.
    Saygin, Caner
    Brammer, Jonathan
    Penza, Sam
    Saad, Ayman
    Jaglowski, Samantha M.
    William, Basem M.
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8901 - 8906
  • [39] Engineering BCMA-CAR T cells to overcome CD19-negative relapse in B cell non-Hodgkin lymphomas
    Antonana-Vildosola, A.
    Perez-Amill, L.
    Sune, G.
    Castella, M.
    Najjar, A.
    Urbano, A.
    Martin-Antonio, B.
    HUMAN GENE THERAPY, 2019, 30 (11) : A67 - A68
  • [40] Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas
    Lemoine, Jean
    Morin, Florence
    Di Blasi, Roberta
    Vercellino, Laetitia
    Cuffel, Alexis
    Benlachgar, Naoufal
    Larghero, Jerome
    Madelaine, Isabelle
    Calvani, Julien
    Meignin, Veronique
    Caillat-Zucman, Sophie
    Chevret, Sylvie
    BLOOD, 2021, 138
12345